Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

FDA: New Email List on HIV/AIDS

July 27, 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The U.S. Food and Drug Administration has started an email list anyone can join, to provide AIDS-related information from the Agency. The official announcement, below, gives details.

Note: The sign-up process shows users confusing options -- but they can be ignored. Just stay with the defaults provided, unless you know you want something else.

"An e-mail list has been established by the Division of Antiviral Drug Products (Center for Drug Evaluation and Research) and the Office of Special Health Issues (Office of the Commissioner) of the Food and Drug Administration (FDA) to provide updates on safety and regulatory issues related to HIV/AIDS products.

"The purpose of this e-mail list is to give patients, industry, academia, other government agencies and other interested parties one source for FDA HIV/AIDS related information. Information such as product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment will be distributed through this e-mail list.

Advertisement
"To join the e-mail list, please go to http://list.nih.gov/archives/fda-hiv-aids.html. Your name and e-mail address is considered confidential and will not be released.

"If you are interested in regulatory guidance and requirements for blood safety, you should also register for the FDA's Center for Biologics Evaluation and Research e-mail list at http://www.fda.gov/cber/pubinfo/elists.htm.

"The HIV/AIDS e-mail list is not intended or designed to accept comments or input, but merely to disseminate important HIV/AIDS-related information and alert interested parties about HIV/AIDS related issues for public comment.

"Information will be distributed through this e-mail list as it becomes available, rather than on a regularly scheduled basis.

"For additional information about the FDA HIV/AIDS e-mail list please contact the Office of Special Health Issues at oshi@oc.fda.gov."


ISSN # 1052-4207

Copyright 2001 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.


Back to the AIDS Treatment News July 27, 2001 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues

Tools
 

Advertisement